While Trump is arguably one of the most unpredictable presidents of all time, investors, analysts, and market strategists often try to use the past to look for clues regarding what could happen in the future. Will the stock market soar or crash under President Trump in 2026? History won't tell us for sure, but here's what it shows might happen.

Dow, S&P, Nasdaq all in red. Stocks fell Wednesday as weak earnings from Texas Instruments (-4%) and Netflix (-9%) weighed on the major averages. Dow dropped 147 points (0.3%), S&P 500 fell 0.4%, Nasdaq slid 0.

Lately, there's talk of an AI bubble, a runup in the prices of tech stocks fueled by enthusiasm over artificial intelligence. Several tech giants report earnings in late October, numbers that could inflate the bubble further – or cause it to pop.

Andrew Ross Sorkin shares his journey from Wall Street to AI, exploring how storytelling drives markets, media, and ambition.

Talk of a 2025 recession abated this summer, but economists noted a sense of instability among consumers, who were spending less, and among businesses, which were hiring less.

Now a growing number of experts warn that these new highs could be followed by new lows — a dire risk to the 62% of Americans who collectively own stocks worth $51 trillion. (1)

Despite a rough patch in the earlier part of the year in response to the Trump administration's tariff plan, it has been a good year so far for the stock market's three main indexes: the S&P 500 (SNPINDEX: ^GSPC), the Nasdaq Composite, and the Dow Jones. Through Oct. 21, they're up 14.7%, 19%, and 10.8% year to date, respectively.

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and behavioral finance.

Living off of dividends is a common strategy for retirees. Of course, for it to work, you need to amass a pretty sizable portfolio. Let’s say your portfolio gives you a dividend yield of 4%. If you have $500,

The massive stock decline was driven by a confluence of negative financial and operational news. Fiserv’s results missed Wall Street expectations on two major

UniQure NV's stock plummeted over 54% after the FDA deemed the clinical data for its Huntington's disease gene therapy AMT-130 inadequate. Investors are left questioning the future of the therapy and the broader gene therapy pipeline.